Monoclonal Antibody to Coagulation Factor II (F2)
| Code | Size | Price |
|---|
| MAA820Ra29-20ul | 20uL | £89.00 |
Quantity:
| MAA820Ra29-100ul | 100ul | £168.00 |
Quantity:
| MAA820Ra29-200ul | 200ul | £227.00 |
Quantity:
| MAA820Ra29-1ml | 1ml | £522.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG2b Kappa
Antibody Clonality: Monoclonal
Antibody Clone: C10
Regulatory Status: RUO
Target Species: Rat
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
FII; TM; PT; Thrombin; Prothrombin; Pro-Thrombin; Activation peptide fragment 1; Activation peptide fragment 2
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Coagulation Factor II
Potency (Clone Number):
C10
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Coagulation Factor II (F2) | RPA820Ra02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||